Fusion Antibodies plc (AIM:FAB)

Revenue by Segment

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Research, Development and Manufacture of Recombinant Proteins and Antibodies	2.11M	1.97M	1.14M	2.90M	4.80M
Total	2.11M	1.97M	1.14M	2.90M	4.80M

Revenue by Geography

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
United Kingdom	652.00K	569.00K	195.00K	621.00K	724.00K
Rest of Europe	505.00K	101.00K	95.00K	409.00K	1.39M
North America and Rest Of World	953.00K	1.30M	846.00K	1.87M	-
North America	-	-	-	-	2.00M
Rest of World	-	-	-	-	681.00K
Total	2.11M	1.97M	1.14M	2.90M	4.80M

Data Source: S&P Global Market Intelligence Last updated: Sep 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 10, 2026

Data Sources Report a data error